Posts

What is Recurrent Brief Depression?

Introduction

Recurrent brief depression (RBD) defines a mental disorder characterised by intermittent depressive episodes, not related to menstrual cycles in women, occurring between approximately 6-12 times per year, over at least one year or more fulfilling the diagnostic criteria for major depressive episodes (DSM-IV and ICD-10) except for duration which in RBD is less than 14 days, typically 5-7 days.

Despite the short duration of the depressive episodes, such episodes are severe, and suicidal ideation and impaired function is rather common. The majority of patients with RBD also report symptoms of anxiety and increased irritability. Hypersomnia is also rather frequent. About 1/2 of patients fulfilling diagnostic criteria for RBD may have additional short episodes of brief hypomania which is a severity marker of RBD. RBD may be the only mental disorder present, but RBD may also occur as part of a history of recurrent major depressive episodes or bipolar disorders. RBD is also seen among some patients with personality disorders.

Prevalence

The lifetime prevalence of RBD has been estimated at 2.6-10.0%, and the one-year prevalence at 5.0-8.2%. The WHO project on “Psychological problems in general health care”, which was based on primary care samples, reported a one-year prevalence of 3.7-9.9%. However none of these studies differentiate between RBD with and without a history of other mood disorders (e.g. major depression). DSM-IV field trial estimated the lifetime of RBD only to be about 2%.

Brief History

Disorders characterised by periods with depressive episodes lasting hours to days have been described since 1852 and have been labelled “periodic melancholia”, “intermittent depressive disorder” or “very brief depression”. The third version of the Diagnostic and Statistical Manual of Mental Disorders (1980), which relied heavily on findings from studies conducted in psychiatric in- and out-patient settings, required at least 14 days duration for a diagnosis of depression. No diagnostic category was allocated a depressive episode of shorter duration. Thus, intermittent depressive disorder, included in the Research Diagnostic Criteria (1975) was considered to identify minor versions of major depression (“minor depression”) and not included in the DSM-III.

However, based on data from epidemiological studies, the Swiss psychiatrist and researcher, Jules Angst, coined the concept “recurrent brief depression” (RBD) and provided diagnostic criteria for this type of mood disorder in 1985. Several other European studies independently confirmed the occurrence of RBD in the general population and clinical samples. RBD was thus included in the 10th classification of mental and behavioural disorders (ICD-10 F38.1) published by the World Health Organisation in 1992 (WHO, 1992; WHO, 1993). Less frequent episodes of brief depressions were labelled infrequent brief depression and not included in ICD-10. The American classification system of mental disorders, DSM-IV (1994), provided provisional diagnostic criteria for RBD, but decided to await further studies before including RBD in the classification system. The fate of RBD in DSM-5, expected to occur in 2013, is not known.

Causes

The cause (aetiology) of RBD is unknown, but recent findings may suggest a link between RBD and bipolar disorders, pointing to the importance of genetic factors. A small subgroup of patients with RBD has temporal lobe epilepsy.

Diagnosis

From the International Statistical Classification of Mental and Behavioral Disorders:

F33 Recurrent depressive disorder

  • G1. There has been at least one previous episode, mild (F32.0), moderate (F32.1), or severe (F32.2 or F32.3), lasting a maximum of two weeks and separated from the current episode by at least two months free from any significant mood symptoms.
  • G2. At no time in the past has there been an episode meeting the criteria or hypomanic or manic episode (F30.-).
  • G3. Most commonly used exclusion criteria: the episode is not attributable to psychoactive substance use (F1) or any organic mental disorder, in the sense of F0. It is recommended to specify the predominant type of previous episodes (mild, moderate, severe, uncertain).

F33.0 Recurrent depressive disorder, current episode mild

  • A. The general criteria for recurrent depressive disorder (F33) are met.
  • B. The current episode meets the criteria for depressive episode, mild severity (F32.0).
  • A fifth character may be used to specify the presence of the somatic syndrome, as defined in F32, in the current episode:
    • F33.00 without somatic syndrome.
    • F33.01 with somatic syndrome.

F33.1 Recurrent depressive disorder, current episode moderate

  • A. The general criteria for recurrent depressive disorders (F33) are met.
  • B. The current episode meets the criteria for depressive episode, moderate severity (F32.1).
  • A fifth character may be used to specify the presence of the somatic syndrome, as defined in F32, in the current episode:
    • F33.10 without somatic syndrome
    • F33.11 with somatic syndrome.

F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms

  • A. The general criteria for recurrent depressive disorders (F33) are met.
  • B. The current episode meets the criteria for severe depressive episode without psychotic symptoms (F32.2).

F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms

  • A. The general criteria for recurrent depressive disorders (F33) are met.
  • B. The current episode meets the criteria for severe depressive episode with psychotic symptoms (F32.3). A fifth character may be used to specify whether the psychotic symptoms are congruent or incongruent with the mood:
    • F33.30 with mood congruent psychotic symptoms.
    • F33.31 with mood incongruent psychotic symptoms.

F33.4 Recurrent depressive disorder, currently in remission

  • A. The general criteria for recurrent depressive disorder (F33) have been met in the past.
  • B. The current state does not meet the criteria for a depressive episode (F32.-) of any severity, or for any other disorder in F3 (the patient may receive treatment to reduce the risk of further episodes).

F33.8 Other recurrent depressive disorders.

F33.9 Recurrent depressive disorder, unspecified.

Treatment

Both psychotherapy as well as different drugs (e.g. serotonin reuptake inhibitors – SSRIs or mood stabilisers, e.g. lithium, antiepileptics) have been suggested as treatments. However, no randomised controlled treatment trial of RBD has been conducted.

What is Paranoid Personality Disorder?

Introduction

Paranoid personality disorder (PPD) is a mental illness characterised by paranoid delusions, and a pervasive, long-standing suspiciousness and generalised mistrust of others.

People with this personality disorder may be hypersensitive, easily insulted, and habitually relate to the world by vigilant scanning of the environment for clues or suggestions that may validate their fears or biases. They are eager observers. They think they are in danger and look for signs and threats of that danger, potentially not appreciating other interpretations or evidence.

They tend to be guarded and suspicious and have quite constricted emotional lives. Their reduced capacity for meaningful emotional involvement and the general pattern of isolated withdrawal often lend a quality of schizoid isolation to their life experience. People with PPD may have a tendency to bear grudges, suspiciousness, tendency to interpret others’ actions as hostile, persistent tendency to self-reference, or a tenacious sense of personal right. Patients with this disorder can also have significant comorbidity with other personality disorders (such as schizotypal, schizoid, narcissistic, avoidant and borderline).

Epidemiology

PPD occurs in about 0.5-2.5% of the general population. It is seen in 2-10% of psychiatric outpatients. It is more common in males.

Brief History

Paranoid personality disorder is listed in DSM-V and was included in all previous versions of the DSM. One of the earliest descriptions of the paranoid personality comes from the French psychiatrist Valentin Magnan who described a “fragile personality” that showed idiosyncratic thinking, hypochondriasis, undue sensitivity, referential thinking and suspiciousness.

Closely related to this description is Emil Kraepelin’s description from 1905 of a pseudo-querulous personality who is “always on the alert to find grievance, but without delusions”, vain, self-absorbed, sensitive, irritable, litigious, obstinate, and living at strife with the world. In 1921, he renamed the condition paranoid personality and described these people as distrustful, feeling unjustly treated and feeling subjected to hostility, interference and oppression. He also observed a contradiction in these personalities: on the one hand, they stubbornly hold on to their unusual ideas, on the other hand, they often accept every piece of gossip as the truth. Kraepelin also noted that paranoid personalities were often present in people who later developed paranoid psychosis. Subsequent writers also considered traits like suspiciousness and hostility to predispose people to developing delusional illnesses, particularly “late paraphrenias” of old age.

Following Kraepelin, Eugen Bleuler described “contentious psychopathy” or “paranoid constitution” as displaying the characteristic triad of suspiciousness, grandiosity and feelings of persecution. He also emphasized that these people’s false assumptions do not attain the form of real delusion.

Ernst Kretschmer emphasized the sensitive inner core of the paranoia-prone personality: they feel shy and inadequate but at the same time they have an attitude of entitlement. They attribute their failures to the machinations of others but secretly to their own inadequacy. They experience constant tension between feelings of self-importance and experiencing the environment as unappreciative and humiliating.

Karl Jaspers, a German phenomenologist, described “self-insecure” personalities who resemble the paranoid personality. According to Jaspers, such people experience inner humiliation, brought about by outside experiences and their interpretations of them. They have an urge to get external confirmation to their self-deprecation and that makes them see insults in the behaviour of other people. They suffer from every slight because they seek the real reason for them in themselves. This kind of insecurity leads to overcompensation: compulsive formality, strict social observances and exaggerated displays of assurance.

In 1950, Kurt Schneider described the “fanatic psychopaths” and divided them into two categories: the combative type that is very insistent about his false notions and actively quarrelsome, and the eccentric type that is passive, secretive, vulnerable to esoteric sects but nonetheless suspicious about others.

The descriptions of Leonhard and Sheperd from the sixties describe paranoid people as overvaluing their abilities and attributing their failure to the ill-will of others; they also mention that their interpersonal relations are disturbed and they are in constant conflict with others.

In 1975, Polatin described the paranoid personality as rigid, suspicious, watchful, self-centred and selfish, inwardly hypersensitive but emotionally undemonstrative. However, when there is a difference of opinion, the underlying mistrust, authoritarianism and rage burst through.

In the 1980s, paranoid personality disorder received little attention, and when it did receive it, the focus was on its potential relationship to paranoid schizophrenia. The most significant contribution of this decade comes from Theodore Millon who divided the features of paranoid personality disorder to four categories:

  1. Behavioural characteristics of vigilance, abrasive irritability and counterattack.
  2. Complaints indicating oversensitivity, social isolation and mistrust.
  3. The dynamics of denying personal insecurities, attributing these to others and self-inflation through grandiose fantasies.
  4. Coping style of detesting dependence and hostile distancing of oneself from others.

Causes

A genetic contribution to paranoid traits and a possible genetic link between this personality disorder and schizophrenia exist. A large long-term Norwegian twin study found paranoid personality disorder to be modestly heritable and to share a portion of its genetic and environmental risk factors with the other cluster A personality disorders, schizoid and schizotypal.

Psychosocial theories implicate projection of negative internal feelings and parental modelling. Cognitive theorists believe the disorder to be a result of an underlying belief that other people are unfriendly in combination with a lack of self-awareness.

Diagnosis

ICD-10

The World Health Organisation’s ICD-10 lists paranoid personality disorder under (F60.0). It is a requirement of ICD-10 that a diagnosis of any specific personality disorder also satisfies a set of general personality disorder criteria. It is also pointed out that for different cultures it may be necessary to develop specific sets of criteria with regard to social norms, rules and other obligations.

PPD is characterised by at least three of the following symptoms:

  1. Excessive sensitivity to setbacks and rebuffs;
  2. Tendency to bear grudges persistently (i.e. refusal to forgive insults and injuries or slights);
  3. Suspiciousness and a pervasive tendency to distort experience by misconstruing the neutral or friendly actions of others as hostile or contemptuous;
  4. A combative and tenacious sense of self-righteousness out of keeping with the actual situation;
  5. Recurrent suspicions, without justification, regarding sexual fidelity of spouse or sexual partner;
  6. Tendency to experience excessive self-aggrandising, manifest in a persistent self-referential attitude;
  7. Preoccupation with unsubstantiated “conspiratorial” explanations of events both immediate to the patient and in the world at large.

Includes: expansive paranoid, fanatic, querulant and sensitive paranoid personality disorder.

Excludes: delusional disorder and schizophrenia.

DSM-5

The American Psychiatric Association’s DSM-5 has similar criteria for paranoid personality disorder. They require in general the presence of lasting distrust and suspicion of others, interpreting their motives as malevolent, from an early adult age, occurring in a range of situations. Four of seven specific issues must be present, which include different types of suspicions or doubt (such as of being exploited, or that remarks have a subtle threatening meaning), in some cases regarding others in general or specifically friends or partners, and in some cases referring to a response of holding grudges or reacting angrily.

PPD is characterised by a pervasive distrust and suspiciousness of others such that their motives are interpreted as malevolent, beginning by early adulthood and present in a variety of contexts. To qualify for a diagnosis, the patient must meet at least four out of the following criteria:

  1. Suspects, without sufficient basis, that others are exploiting, harming, or deceiving them.
  2. Is preoccupied with unjustified doubts about the loyalty or trustworthiness of friends or associates.
  3. Is reluctant to confide in others because of unwarranted fear that the information will be used maliciously against them.
  4. Reads hidden demeaning or threatening meanings into benign remarks or events.
  5. Persistently bears grudges (i.e., is unforgiving of insults, injuries, or slights).
  6. Perceives attacks on their character or reputation that are not apparent to others and is quick to react angrily or to counterattack.
  7. Has recurrent suspicions, without justification, regarding fidelity of spouse or sexual partner.

The DSM-5 lists paranoid personality disorder essentially unchanged from the DSM-IV-TR version and lists associated features that describe it in a more quotidian way. These features include suspiciousness, intimacy avoidance, hostility and unusual beliefs/experiences.

Other

Various researchers and clinicians may propose varieties and subsets or dimensions of personality related to the official diagnoses. Psychologist Theodore Millon has proposed five subtypes of paranoid personality (table below).

SubtypeFeatures
Obdurate paranoid (including compulsive features)Self-assertive, unyielding, stubborn, steely, implacable, unrelenting, dyspeptic, peevish, and cranky stance; legalistic and self-righteous; discharges previously restrained hostility; renounces self-other conflict.
Fanatic paranoid (including narcissistic features)Grandiose delusions are irrational and flimsy; pretentious, expensive supercilious contempt and arrogance toward others; lost pride re-established with extravagant claims and fantasies.
Querulous paranoid (including negativistic features)Contentious, cavilling, fractious, argumentative, fault-finding, unaccommodating, resentful, choleric, jealous, peevish, sullen, endless wrangles, whiny, waspish, snappish.
Insular paranoid (including avoidant features)Reclusive, self-sequestered, hermitical; self-protectively secluded from omnipresent threats and destructive forces; hypervigilant and defensive against imagined dangers.
Malignant paranoid (including sadistic features)Belligerent, cantankerous, intimidating, vengeful, callous, and tyrannical; hostility vented primarily in fantasy; projects own venomous outlook onto others; persecutory delusions.

Differential Diagnosis

Paranoid personality disorder can involve, in response to stress, very brief psychotic episodes (lasting minutes to hours). The paranoid may also be at greater than average risk of experiencing major depressive disorder, agoraphobia, social anxiety disorder, obsessive-compulsive disorder or alcohol and substance-related disorders. Criteria for other personality disorder diagnoses are commonly also met, such as:

Treatment

Because of reduced levels of trust, there can be challenges in treating PPD. However, psychotherapy, antidepressants, antipsychotics and anti-anxiety medications can play a role when a person is receptive to intervention.

On This Day … 22 April

People (Births)

  • 1884 – Otto Rank, Austrian-American psychologist and academic (d. 1939).

Otto Rank

Otto Rank (22 April 1884 to 31 October 1939) was an Austrian psychoanalyst, writer, and teacher.

Born in Vienna, he was one of Sigmund Freud’s closest colleagues for 20 years, a prolific writer on psychoanalytic themes, editor of the two leading analytic journals of the era, managing director of Freud’s publishing house, and a creative theorist and therapist.

In 1926, Rank left Vienna for Paris and, for the remainder of his life, led a successful career as a lecturer, writer, and therapist in France and the United States.

What is an Over-the-Counter Drug?

Introduction

Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription.

In many countries, OTC drugs are selected by a regulatory agency to ensure that they contain ingredients that are safe and effective when used without a physician’s care. OTC drugs are usually regulated according to their active pharmaceutical ingredient (API) rather than final products. By regulating APIs instead of specific drug formulations, governments allow manufacturers the freedom to formulate ingredients, or combinations of ingredients, into proprietary mixtures.

The term OTC refers to a medication that can be purchased without a medical prescription. In contrast, prescription drugs require a prescription from a doctor and should only be used by the prescribed individual. Some drugs may be legally classified as OTC (i.e. no prescription is required), but may only be dispensed by a pharmacist after an assessment of the patient’s needs or the provision of patient education. Regulations detailing the establishments where drugs may be sold, who is authorised to dispense them, and whether a prescription is required vary considerably from country to country.

Usage

As of 2011, around a third of older adults in the US reportedly used OTC drugs. By 2018, the prevalence of use by adults in the US as first-line treatment for minor illnesses had reached 81%.

Regulation by Country

Canada

In Canada, there are four drug schedules:

  • Schedule 1: Requires a prescription for sale and is provided to the public by a licensed pharmacist.
  • Schedule 2: Does not require a prescription but requires an assessment by a pharmacist prior to sale. These drugs are kept in an area of the pharmacy where there is no public access and may also be referred to as “behind-the-counter” drugs.
  • Schedule 3: Does not require a prescription but must be kept in an area under the supervision of a pharmacist. These drugs are kept in an area of the retail outlet where self-selection is possible, but a pharmacist must be available to assist in the self-selection of medication if required.
  • Unscheduled: Does not require a prescription and may be sold in any retail outlet.

All medications other than Schedule 1 may be considered an OTC drug, as they do not require prescriptions for sale. While the National Association of Pharmacy Regulatory Authorities provides recommendations on the scheduling of drugs for sale in Canada, each province may determine its own scheduling. The drugs found in each schedule may vary from province to province.

Indonesia or India

In November 2016, India’s Drug Consultative Committee announced it was embarking on establishing a definition of drugs which could be dispensed without a prescription. Prior to this, the general assumption was that any drug which did not fall into a prescription schedule could be purchased without a prescription. However, the needed definition had not been enacted by early 2018. The lack of a legal definition for OTC drugs has led to this US$4 billion market segment being effectively unregulated.

Netherlands

In the Netherlands, there are four categories:

  • UR (Uitsluitend Recept): prescription only.
  • UA (Uitsluitend Apotheek): pharmacist only.
  • UAD (Uitsluitend Apotheek of Drogist): pharmacist or drugstore only.
  • AV (Algemene Verkoop): may be sold in general stores.

A drug that is UA may be sold OTC but only by pharmacists. The drug can be on the shelves like any other product. Examples are domperidone, 400 mg ibuprofen up to 50 tablets and dextromethorphan. A drug that is UAD can also be sold at drugstores, stores where no prescription can be filed and there is only a relatively small selection of popular drugs like painkillers and cough medicine. The drugs are usually on the shelves, and the store also sells items like toys, gadgets, perfumes and homeopathic products. The drugs in this category have limited risk and addiction potential. Examples are naproxen and diclofenac in small amounts, cinnarizine, 400 mg ibuprofen up to 20 tablets and also 500 mg paracetamol up to 50 tablets. Drugs in the AV category can be sold at supermarkets, gas stations, etc. and include only drugs with minimal risk to the public, like paracetamol up to 20 tablets, 200 mg ibuprofen up to 10 tablets, cetirizine and loperamide.

United States

In the United States, the manufacture and sale of OTC substances are regulated by the Food and Drug Administration (FDA). The FDA requires that all “new drugs” obtain a New Drug Application (NDA) before entering interstate commerce, but the act exempts any drugs generally recognised as safe and effective (GRAS/E). To deal with the vast number of OTC drugs that were already on the market before the requirement that all drugs obtain an NDA, the FDA created the OTC monograph system to review classes of drugs and to categorise them as GRAS/E after review by expert panels. Certain classes of OTC drugs would not be required to obtain an NDA and could remain on the market if they conformed to the monograph guidelines for doses, labelling, and warnings finalized in the Code of Federal Regulations.

Thus, an OTC drug product is allowed to be marketed either (1) pursuant to an FDA monograph or (2) pursuant to an NDA for products that do not fit within a specific monograph. There is also the possibility that certain OTC drug products are marketed under the grandfathering provisions of the Federal Food, Drug, and Cosmetic Act, but the FDA has never formally acknowledged that any legitimate grandfathered OTC drug exists.

Examples of OTC substances approved in the United States are sunscreens, anti-microbial and anti-fungal products, external and internal analgesics such as lidocaine and aspirin, psoriasis and eczema topical treatments, anti-dandruff shampoos containing coal tar, and other topical products with a therapeutic effect.

The Federal Trade Commission regulates advertising of OTC products, in contrast to prescription drug advertising, which is regulated by the FDA.

The FDA requires OTC products to be labelled with an approved “Drug Facts” label to educate consumers about their medications. The labels comply to a standard format and are intended to be easy for typical consumers to understand. Drug Facts labels include information on the product’s active ingredient(s), indications and purpose, safety warnings, directions for use, and inactive ingredients.

The 2020 Coronavirus Aid, Relief, and Economic Security Act (CARES Act) includes reforms that modernise the way certain OTC drugs are regulated in the United States. Many OTC monographs need to be updated but updating or changing an OTC monograph requires the slow and burdensome notice-and-comment rulemaking process. The CARES Act includes OTC monograph reform provisions that replace the rulemaking process with an administrative order process.

Restricted Over-the-Counter Substances (US)

An ill-defined third category of substances is products having over-the-counter status from the FDA while being simultaneously subject to other restrictions on sale. While they are legally classified as OTC drugs, they are typically stored behind the counter and are sold only in stores that are registered with their state. They may be unavailable in convenience and grocery stores that stock other non-restricted OTC medications.

For example, many drugstores have moved products containing pseudoephedrine, an OTC product, into locations where customers must ask a pharmacist for them. A prescription is not required; the change has been made in an effort to reduce methamphetamine production. Since the passage of the Illinois Methamphetamine Precursor Control Act and the subsequent federal Combat Methamphetamine Epidemic Act of 2005, the purchase of pseudoephedrine is restricted. Sellers of pseudoephedrine must obtain and record the identity of the purchaser and enforce quantity restrictions. Some states may have more stringent requirements (such as Oregon, where a medical prescription is required to purchase any quantity of pseudoephedrine). After initial attempts to control methamphetamine use (by requiring documentation of sale with government issued ID as well as limits on the quantity an individual could purchase) failed to realise meaningful reductions in methamphetamine use and production, Mississippi passed House Bill 512 in the State Senate on February 2, 2010 “to require a prescription from a licensed medical professional to purchase over-the-counter medicines with pseudoephedrine, ephedrine, or any other precursor chemical that can readily and illicitly be converted into methamphetamine, Methcathinone or any active/scheduled analogues of Phenylethylamines/ amphetamine.” However, products containing the substance are still OTC in most states, since no prescription is required.

A similar regulation once applied to some forms of emergency contraception. However, on 25 February 2014, the FDA approved generic one-pill emergency contraception products for unrestricted sale on the shelf. There is no age limit or need for ID to purchase.

Furthermore, some Schedule V controlled substances may be classified as OTC products in certain states. Such drugs are sold without a prescription but are subject to record-keeping rules and quantity and/or age restrictions, and they must be dispensed by a pharmacy. Finally, pharmacies frequently require a prescription for Schedule V drugs as a matter of policy, despite their OTC status according to applicable laws and regulations.

United Kingdom

In the United Kingdom, medication is governed by the Medicines Regulations 2012. Medication falls into one of three categories:

  • Prescription Only Medication (POM), which are legally available only with a valid prescription from a prescriber.
    • A pharmacist has to be on the premises for POM medicines to be dispensed, required by law.
    • The medicine has been specifically prescribed for the patient holding the prescription, so it is considered safe for only the recipient to take.
    • Just a small example of these include most antibiotics and all antidepressants or antidiabetic medications.
    • Drugs included as POM are high-strength painkillers such as oxycodone and tramadol, medications such as Zolpidem (Ambien), diazepam (Valium), and certain topical preparations such as corticosteroids.
    • These medicines are often sold by drug dealers, especially those marked as “CD POM,” which are controlled due to abuse risk such as dipipanone, temazepam, and methadone.
  • General Sales List (GSL), available off the shelf with no pharmacy training required to sell (so they can be sold anywhere, such as supermarkets).
    • In general, they are considered safe for most people when taken correctly.
    • Examples of these include 16-packs (or less) of painkillers such as paracetamol and ibuprofen as well as a host of other safe medications such as small pack sizes of antiallergy tablets, laxative medication, and skin creams.
  • Pharmacy Medicines (P) are medicines that are legally neither a POM or GSL medication.
    • These can be sold from a registered pharmacy but should not be available for self-selection (although directions to discuss a ‘P’ product may be allocated shelf space with associated GSL items).
    • ‘P’ medications are reserved from the GSL list as they are either associated with a need for advice on use, or used in conditions which may require referral to a medical prescriber.
    • Suitable trained counter assistants may sell a ‘P’ medication under the supervision of a pharmacist and will ask questions to determine if the customer needs to be referred for a discussion with a pharmacist.
    • Some ‘POM’ medicines are available for use in certain situations and doses as ‘P’ medicines.

If it is not appropriate to sell a ‘P’ medication – i.e. the condition is not suitable for self-management and requires referral to a medical prescriber – then a sale should not occur and the pharmacist has a legal and professional obligation to refer this on to an appropriate service.

Examples of these include some sleep aid tablets such as Nytol, human deworming tablets such as Mebendazole, painkillers with small amounts of codeine (up to 12.8 mg per tablet), and pseudoephedrine. Medication available only with a prescription is marked somewhere on the box/container with [POM]. Pharmacy-only products are marked with [P]. A prescription is not required for [P] medicines, and pharmacy sales assistants are required by Royal Pharmaceutical Society codes to ask certain questions, which varies for what the customer says. If they ask for a specific product, the pharmacy assistant must ask “Who is it for,” “How long have you had the symptoms,” “Are you allergic to any medication,” “Are you taking any medication” (‘WHAM’ questions). If a customer asks for a remedy, e.g. hay fever, then the two WHAM questions must be followed “Who is it for,” “What are the symptoms,” “How long have you had the symptoms,” “Have you taken any action towards your symptoms,” and “Are you taking any other medication.” It is with this information that the pharmacist can halt the sale, if need be. No [POM], [P] or [GSL] products that are stocked in a pharmacy can be sold, dispensed, or pre-made until a responsible pharmacist is signed in and on the premises. Some medication available in supermarkets and petrol stations is sold only in smaller packet sizes. Often, larger packs will be marked as [P] and available only from a pharmacy. Frequently, customers buying larger-than-usual doses of [P] medicines (such as DXM, promethazine, codeine or Gee’s linctus) will be queried, due to the possibility of abuse.

Transitions between Prescription and OTC

As a general rule, over-the-counter drugs have to be used primarily to treat a condition that does not require the direct supervision of a doctor and must be proven to be reasonably safe and well tolerated. OTC drugs are usually also required to have little or no abuse potential, although in some areas drugs such as codeine are available OTC (usually in strictly limited formulations or requiring paperwork or identification to be submitted during purchase).

Over time, often 3-6 years, drugs that prove themselves safe and appropriate as prescription medicines may be switched from prescription to OTC.[citation needed] An example of this is diphenhydramine (Benadryl), an anti-histamine which once required a prescription but now is available OTC nearly everywhere. More recent examples are cimetidine and loratadine in the United States, and ibuprofen in Australia.

It is somewhat unusual for an OTC drug to be withdrawn from the market as a result of safety concerns, rather than market forces, though it does happen occasionally. For example, phenylpropanolamine was removed from sale in the United States over concern regarding strokes in young women. A study has been done examining consumer’s perceptions about the risk of and access to non-prescription medication. The study concluded that a small percentage of consumers prefer having access to medication over potential risks of taking non-prescribed medication. Ranitidine was withdrawn from multiple markets due to concerns over the carcinogen N-nitrosodimethylamine (NDMA).

In the United Kingdom, it was announced in February 2007 that Boots the Chemist would try OTC sales of Viagra in stores in Manchester, England (previous available as prescription only). Men aged between 30 and 65 could buy four tablets after a consultation with a pharmacist.

What is the Negativistic Personality Disorder?

Introduction

Negativistic personality disorder is characterised by procrastination, covert obstructionism, inefficiency and stubbornness.

The current version of the Diagnostic and Statistical Manual of Mental Disorders no longer uses this phrase or label, and it is not one of the ten listed specific personality disorders. The previous edition, the revision IV (DSM-IV) describes passive-aggressive personality disorder as a proposed disorder involving a “pervasive pattern of negativistic attitudes and passive resistance to demands for adequate performance” in a variety of contexts.

Passive-aggressive behaviour is the obligatory symptom of the passive-aggressive personality disorder. Persons with passive-aggressive personality disorder are characterised by procrastination, covert obstructionism, inefficiency and stubbornness.

Brief History

In the first version of the Diagnostic and Statistical Manual of Mental Disorders, DSM-I, in 1952, the Passive-aggressive was defined in a narrow way, grouped together with the passive-dependent.

The DSM-III-R stated in 1987 that Passive-aggressive disorder is typified by, among other things, “fail[ing] to do the laundry or to stock the kitchen with food because of procrastination and dawdling.”

Causes

Passive-aggressive disorder may stem from a specific childhood stimulus (e.g. alcohol/drug addicted parents, bullying, abuse) in an environment where it was not safe to express frustration or anger. Families in which the honest expression of feelings is forbidden tend to teach children to repress and deny their feelings and to use other channels to express their frustration. For example, if physical and psychological punishment were to be dealt to children who express anger, they would be inclined to be passive aggressive.

Children who sugarcoat hostility may have difficulties being assertive, never developing better coping strategies or skills for self-expression. They can become adults who, beneath a “seductive veneer,” harbour “vindictive intent,” in the words of Timothy F. Murphy and Loriann Oberlin. Alternatively individuals may simply have difficulty being as directly aggressive or assertive as others. Martin Kantor suggests three areas that contribute to passive-aggressive anger in individuals: conflicts about dependency, control, and competition, and that a person may be termed passive-aggressive if they behave so to few people on most occasions.

Murphy and Oberlin also see passive aggression as part of a larger umbrella of hidden anger stemming from ten traits of the angry child or adult. These traits include making one’s own misery, the inability to analyse problems, blaming others, turning bad feelings into angry ones, attacking people, lacking empathy, using anger to gain power, confusing anger with self-esteem, and indulging in negative self-talk. Lastly, the authors point out that those who hide their anger can be nice when they wish to be.

Diagnosis

Diagnostic and Statistical Manual

With the publication of the DSM-5, this label has been largely disregarded. The equivalent DSM-5 diagnostic label would be “Other specified personality and unspecified personality disorder,” as the individual may meet general criteria for a personality disorder, but does not meet the trait-based diagnostic criteria for any specific personality disorder (p.645).

Passive-aggressive [personality disorder] was listed as an Axis II personality disorder in the DSM-III-R, but was moved in the DSM-IV to Appendix B (“Criteria Sets and Axes Provided for Further Study”) because of controversy and the need for further research on how to also categorise the behaviours in a future edition. According to DSM-IV, people with passive-aggressive personality disorder are “often overtly ambivalent, wavering indecisively from one course of action to its opposite. They may follow an erratic path that causes endless wrangles with others and disappointment for themselves.” Characteristic of these persons is an “intense conflict between dependence on others and the desire for self-assertion.” Although exhibiting superficial bravado, their self-confidence is often very poor, and others react to them with hostility and negativity. This diagnosis is not made if the behaviour is exhibited during a major depressive episode or can be attributed to dysthymic disorder.

ICD-10

The 10th revision of the International Classification of Diseases (ICD-10) of the World Health Organisation (WHO) includes passive-aggressive personality disorder in the “other specific personality disorders” rubric (description: “a personality disorder that fits none of the specific rubrics: F60.0-F60.7”). ICD-10 code for “other specific personality disorders” is F60.8. For this psychiatric diagnosis a condition must meet the general criteria for personality disorder listed under F60 in the clinical descriptions and diagnostic guidelines.

The general criteria for personality disorder includes markedly disharmonious behaviour and attitudes (involving such areas of functioning as affectivity – ability to experience affects: emotions or feelings, involving ways of perceiving and thinking, impulse control, arousal, style of relating to others), the abnormal behaviour pattern (enduring, of long standing), personal distress and the abnormal behaviour pattern must be clearly maladaptive and pervasive. Personality disorder must appear during childhood or adolescence and continue into adulthood.

Specific diagnostic criteria of the passive-aggressive personality disorder in the “Diagnostic criteria for research” by WHO is not presented.

Millon’s Subtypes

The psychologist Theodore Millon has proposed four subtypes of ‘negativist’ (‘Passive-aggressive’). Any individual negativist may exhibit none or one of the following:

SubtypeDescriptionPersonality Traits
Vacillating negativistIncluding borderline featuresEmotions fluctuate in bewildering, perplexing, and enigmatic ways; difficult to fathom or comprehend own capricious and mystifying moods; wavers, in flux, and irresolute both subjectively and intrapsychically.
Discontented negativistIncluding depressive featuresGrumbling, petty, testy, cranky, embittered, complaining, fretful, vexed, and moody; gripes behind pretence; avoids confrontation; uses legitimate but trivial complaints.
Circuitous negativistIncluding antisocial and dependent featuresOpposition displayed in a roundabout, labyrinthine, and ambiguous manner, e.g. procrastination, dawdling, forgetfulness, inefficiency, neglect, stubbornness, indirect and devious in venting resentment and resistant behaviours.
Abrasive negativistIncluding sadistic featuresContentious, intransigent, fractious, and quarrelsome; irritable, caustic, debasing, corrosive, and acrimonious, contradicts and derogates; few qualms and little conscience or remorse (no longer a valid diagnosis in DSM).

Treatment

Psychiatrist Kantor suggests a treatment approach using psychodynamic, supportive, cognitive, behavioural and interpersonal therapeutic methods. These methods apply to both the passive-aggressive person and their target victim.

What is a Mental Health Counsellor?

Introduction

A mental health counsellor (MHC), or counsellor, is a person who works with individuals and groups to promote optimum mental and emotional health.

Such persons may help individuals deal with issues associated with addiction and substance abuse; family, parenting, and marital problems; stress management; self-esteem; and aging.

The United States Bureau of Labour Statistics distinguishes “Mental Health Counsellors” from “Social Workers”, “Psychiatrists”, and “Psychologists”.

Duties

The legal definition of a counsellor, and hence the legal scope of practice, varies with jurisdiction. For example, in some jurisdictions across the United States, counsellors, marriage and family therapists, and psychologists have virtually identical definitions: evaluating and treating mental and behavioural disorders.

In spite of such definitions, many mental health professionals reject the medical model (which assumes that clients are “disordered”) in favour of broader viewpoints, such as those that emerged from systems psychology.

Service Users

MHCs work with individuals, couples, families, and groups to address and treat emotional and mental disorders and to promote mental health. Most mental health counsellors in the US work in outpatient and residential care centres, individual and family services, and local governments. They are trained in a variety of therapeutic techniques used to address issues, including depression, anxiety, addiction and substance abuse, suicidal impulses, stress, problems with self-esteem, and grief. They also help with job and career concerns, educational decisions, issues related to mental and emotional health, and family, parenting, marital, or other relationship problems. Some career concerns include helping employees who have mental health conditions to manage their health condition whilst adhering to organisational demands to demonstrate performance and commitment to their work.

MHCs also continue to play a growing role in the military mental health crisis, helping military personnel and their families deal with issues such as PTSD.

MHCs often work closely with other mental health specialists, such as psychiatrists, psychologists, clinical social workers, psychiatric nurses, and school counsellors. Many mental health counsellors look to help their clients have a concise whole body treatment plan that addresses all the needs of the client.

In the United States, MHCs diagnose as well as treat mental illness, though the scope of practice for mental health practitioners varies from state to state.

Regulation

United States

Licensing requirements can vary depending on which state a mental health counsellor practices in. Across the United States, mental health counselling licensure is required to independently practice, but can be practiced without a license if under close supervision of a licensed practitioner. Licensing titles for mental health counsellors vary from state to state:

  • Licensed Mental Health Counsellor (LMHC);
  • Licensed Professional Counsellor (LPC);
  • Licensed Professional Clinical Counsellor (LPCC); and
  • Various forms of these titles may list differently per state statues.

The title “Mental Health Counsellor” (or variation thereof) is often a protected title and thus it may be a violation of state law for persons to hold themselves as such without a proper credential.

A licensed mental health counsellor holds a minimum of a master’s degree in counselling or another closely related field in mental health care. After obtaining a master’s degree, mental health counsellors complete two to three years (depending on various state statutes) of clinical work under the supervision of a licensed or certified mental health professional. The qualifications for licensure are similar to those for marriage and family therapists and for clinical social workers. Becoming a counsellor and using it in daily life to help others to learn more about themselves is not a reason for someone to pursue a degree within this field. Ethics within this profession require the counsellor to remain professional to be able to adequately treat patients. Remaining detached as the witness to a client’s thoughts, feelings, and emotions can be a hard thing to do, but will ultimately reassure a patient that there are no judgement to what they will share. Guiding a patient to understand themselves and their choices is also another aspect of this profession.

On This Day … 20 April

People (Births)

  • 1745 – Philippe Pinel, French physician and psychiatrist (d. 1826).
  • 1915 – Joseph Wolpe, South African psychotherapist and physician (d. 1997).
  • 1920 – Frances Ames, South African neurologist, psychiatrist, and human rights activist (d. 2002).

Philippe Pinel

Philippe Pinel (20 April 1745 to 25 October 1826) was a French physician who was instrumental in the development of a more humane psychological approach to the custody and care of psychiatric patients, referred to today as moral therapy. He also made notable contributions to the classification of mental disorders and has been described by some as “the father of modern psychiatry”.

An 1809 description of a case that Pinel recorded in the second edition of his textbook on insanity is regarded by some as the earliest evidence for the existence of the form of mental disorder later known as dementia praecox or schizophrenia, although Emil Kraepelin is generally accredited with its first conceptualisation.

Joseph Wolpe

Joseph Wolpe (20 April 1915 to 04 December 1997 in Los Angeles) was a South African psychiatrist and one of the most influential figures in behaviour therapy.

Wolpe grew up in South Africa, attending Parktown Boys’ High School and obtaining his MD from the University of the Witwatersrand.

In 1956 Wolpe was awarded a Ford Fellowship and spent a year at Stanford University in the Center for Behavioral Sciences, subsequently returning to South Africa but permanently moving to the United States in 1960 when he accepted a position at the University of Virginia.

In 1965 Wolpe accepted a position at Temple University.

One of the most influential experiences in Wolpe’s life was when he enlisted in the South African army as a medical officer. Wolpe was entrusted to treat soldiers who were diagnosed with what was then called “war neurosis” but today is known as post traumatic stress disorder. The mainstream treatment of the time for soldiers was based on psychoanalytic theory, and involved exploring the trauma while taking a hypnotic agent – so-called narcotherapy. It was believed that having the soldiers talk about their repressed experiences openly would effectively cure their neurosis. However, this was not the case. It was this lack of successful treatment outcomes that forced Wolpe, once a dedicated follower of Freud, to question psychoanalytic therapy and search for more effective treatment options. Wolpe is most well known for his reciprocal inhibition techniques, particularly systematic desensitisation, which revolutionised behavioural therapy.

A Review of General Psychology survey, published in 2002, ranked Wolpe as the 53rd most cited psychologist of the 20th century, an impressive accomplishment accentuated by the fact that Wolpe was a psychiatrist.

Frances Ames

Frances Rix Ames (20 April 1920 to 11 November 2002) was a South African neurologist, psychiatrist, and human rights activist, best known for leading the medical ethics inquiry into the death of anti-apartheid activist Steve Biko, who died from medical neglect after being tortured in police custody. When the South African Medical and Dental Council (SAMDC) declined to discipline the chief district surgeon and his assistant who treated Biko, Ames and a group of five academics and physicians raised funds and fought an eight-year legal battle against the medical establishment. Ames risked her personal safety and academic career in her pursuit of justice, taking the dispute to the South African Supreme Court, where she eventually won the case in 1985.

Born in Pretoria and raised in poverty in Cape Town, Ames became the first woman to receive a Doctor of Medicine degree from the University of Cape Town in 1964. Ames studied the effects of cannabis on the brain and published several articles on the subject. Seeing the therapeutic benefits of cannabis on patients in her own hospital, she became an early proponent of legalisation for medicinal use. She headed the neurology department at Groote Schuur Hospital before retiring in 1985, but continued to lecture at Valkenberg and Alexandra Hospital. After apartheid was dismantled in 1994, Ames testified at the Truth and Reconciliation Commission about her work on the “Biko doctors” medical ethics inquiry. In 1999, Nelson Mandela awarded Ames the Star of South Africa, the country’s highest civilian award, in recognition of her work on behalf of human rights.

Do You Have a Lockdown-Induced Smartphone Addiction?

We are probably all aware that we (or others) spend too much time glued to our electronic devices, but endless months of pandemic-induced ‘house arrest’ may have tipped some people towards a full-blown addiction.

Below are six signs lockdown has left you with a smartphone addiction and what to do about it.

You Can’t SleepThe blue light emitted by phones and other devices messes with melatonin – the hormone that makes you sleepy – making it harder to drift off.
You Feel AnxiousJust because you check your phone a lot does not mean you are addicted, but if the mere thought of not having it to hand worries you, this could indicate you have become dependent.
You’re Stressed Out by Social MediaConstantly scrolling through your news feed means you are more likely to compare yourself to others, feel like you are missing out or get annoyed by what you see and read.
You Can’t Stop Checking Your PhoneA classic sign of addiction is feeling compelled to look at your phone every time you stand still or sit down, while eating dinner and even during activities where it is dangerous to
do so – such as driving.
You Lose TimeIf you find yourself coming back to reality after a scrolling session and wondering where the last hour has gone, it could indicate you have a problem.
You Text More Than TalkYou may find yourself communicating with people via text more often than face to face. This can, in turn, increase feelings of isolation.

How to Break the Cycle

Try a Social Media FastSet a time limit to stay offline and stick to it.
Track your UsageApps such as Moment and BreakFree help you monitor the time you spend scrolling. You might be quite shocked by the results.
Texting!Instead of texting your friend, arrange for a chat or a socially distanced coffee.
Table MannersPower down during every meal and definitely turn your phone off while driving. Even better – put it somewhere well out of reach, like the boot.
Exercise MoreIt sounds simple but every moment spent working out is a moment not wasted online. Physical activity also releases endorphins which improve your mood – bonus!

What is Togetherall?

Formerly called Big White Wall, it is an online mental health platform tool that offers anonymous and immediate peer support to serving personnel, veterans, and families.

It has helped approximately 14,000 members of the military community since it was set up more than nine years ago.

Visit togetherall.com.

What is the World Association of Psychoanalysis?

Introduction

The World Association of Psychoanalysis (WAP) was launched at the initiative of Jacques-Alain Miller in Buenos Aires on 03 January 1992.

It was declared in Paris, four days later, on 07 January.

Background

Its statutes are modelled on Jacques Lacan’s “Founding Act” and adopt the principles outlined in his “Proposition” on the Pass.

Refer to Lacanianism.

Components

The World Association of Psychoanalysis groups include:

  • The École de la Cause freudienne (France);
  • The Escuela de la Orientación Lacaniana (Argentina);
  • The Escuela Lacaniana de Psicoanálisis del Campo Freudiano (Spain);
  • The Scuola lacaniana di psicoanalisi (Italy);
  • The European Federation of the Schools of the WAP;
  • The Escola Brasileira de Psicanálise (Brazil);
  • The Nueva Escuela Lacaniana (Latin America); and
  • The New Lacanian School.

Lacanian

With over 1,500 members worldwide, the WAP stands as the largest institutional structure dedicated to the training of psychoanalysts in the Lacanian orientation.